bc12

BC12 exhibits unusually potent immunomodulatory actions on T lymphocyte function, including inhibition of T cell proliferation and IL-2 cytokine production.

BC12-4 is a novel potent inhibitor of IL-2 secretion, it has potent immunomodulatory activity.

DCN1-UBC12-IN-4 (compound 5p) is an inhibitor of DCN1-UBC12 (IC₅₀ > 10 μM), applicable for investigating cancer cell migration and invasion.

DCN1-UBC12-IN-1 is a potent and specific DCN1-UBC12 inhibitor with an IC50 value of 2.86 nM and anti-cardiac fibrogenic activity.

DCN1-UBC12-IN-2 is a potent and specific DCN1-UBC12 inhibitor with an IC50 value of 9.55 nM, targeting DCN1-UBC12 interactions and inhibiting Ang II-induced activation of cardiac fibroblasts.

BC-1293 is an inhibitor of the E3 ligase subunit FBXO24 that acts by disrupting the interaction between FBXO24 and aspartyl-tRNA synthetase (DARS2). BC-1293 treatment results in increased levels of DARS2, showing its capacity to stabilize this essential enzyme. Furthermore, BC-1293 elevates levels of cytokines including IL-1β, IL-9, MIP-2, and TNF-α in murine models, thereby demonstrating immunostimulatory activity with potential relevance to immune modulation research.

WS-383 free base is a selective and reversible DCN1-UBC12 interaction inhibitor with an IC50 of 11 nM.

WS-383 is a selective, potent and reversible DCN1-UBC12 interaction inhibitor(IC50 of 11 nM).

Bimosiamose disodium has anti-inflammatory effects[1]. Bimosiamose disodium (TBC-1269Z) is a nonoligosaccharide pan-selectin inhibitor with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively.

Bimosiamose has anti-inflammatory effects[1]. Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, L-selectin, and P-selectin respectively.

BC-1215 is an inhibitor of F-box protein 3 (FBXO3, a ubiquitin E3 ligase component, IC50=0.9 μg/mL for IL-1β release).

BC-1258 is a unique small molecule F-box/LRR-repeat protein 2 (FBXL2) activator.